Name: Neuren Pharmaceuticals (NEU) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

NEU

Neuren Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.

Short position

short percentage2.99%

reported shorts3.8M

shares on issue126.774M

Neuren Pharmaceuticals (ASX:NEU) has 2.99% of its shares on issue reported as short positions as of 22 Sept 2026, or about 3,792,976 shares. Over the past 30 days that figure has fallen 1.25 percentage points, and over 90 days it has fallen 3.04 percentage points. Its highest recorded short interest was 6.51% in June 2026. NEU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Weekly context: The 10 most shorted ASX stocks — Week 39, 2026.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

NEU intelligence dossier

Public-source evidence for this company, with industry drill-up links.

Tax paid and taxable income records
Government contracts and public money
Emissions and trade exposure
Political donations and lobbying links

Short interest history & FAQ

NEU Short Interest History

30-day change: -1.25pp
90-day change: -3.04pp
1-year change: -2.07pp
All-time high: 6.51% (June 2026)
All-time low: 0.00% (May 2019)

Is NEU heavily shorted?

Not especially: 2.99% short interest is modest by ASX standards, ranking #111 of 809 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.

How has NEU's short interest changed recently?

Over the past 30 days Neuren Pharmaceuticals's short interest has fallen 1.25 percentage points, and over 90 days it has fallen 3.04 percentage points. The current level is 2.99% of shares on issue.

What is the highest NEU's short interest has been?

Since 2012, Neuren Pharmaceuticals's short interest peaked at 6.51% in June 2026 and bottomed at 0.00% in May 2019.

Where does this data come from?

All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2012. See our methodology.

NEU fundamentals

In the year to 31 Dec 2025, Neuren Pharmaceuticals (ASX:NEU) recorded revenue of A$65.0M. Net margin 47.1% (FY). Figures are in AUD, the company's reporting currency; source: Company filing (extracted), as at 28 Sep 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Strategy fit

How each stock picker strategy reads NEU today

PassFailUnknown (data missing, or not meaningful for this company)

Zanger Breakout
WatchScore 19rank 1013 of 1833
- 1. Explosive growth: unknown. No revenue or EPS growth figure yet
- 2. A recognisable base: fail. No tight base: 26.8% deep, deeper than 25%
- 3. Breakout on heavy volume: fail. No close above the A$23.76 pivot on 1.5x volume in the last 5 sessions; close is -16.6% from the pivot
- 4. Read the market first: fail. XJO in a downtrend: below its 200-day average
- 5. Relative strength: pass. Beat the S&P/ASX 200 by 63.4 points over 3 months
- 6. Liquid enough to trade: pass. A$8.1m average daily turnover over 20 sessions
CAN SLIM
WatchScore 24rank 234 of 1234
- 1. Earnings growth (C and A): unknown. No EPS growth figure yet
- 2. Sales growth: unknown. No revenue growth figure yet
- 3. New highs (N): fail. 16.6% below the 52-week high, more than 5% away
- 4. Leader, not laggard (L): pass. 6-month relative strength +66.3 points, in the top quartile (cut-off +7.8)
- 5. Market direction (M): fail. XJO in a downtrend: below its 200-day average
- 6. Supply and demand (S): pass. A$8.1m average daily turnover over 20 sessions
Minervini Trend Template
WatchScore 49rank 332 of 1768
- 1. Above rising averages: fail. Close A$19.82, 150-day A$15.70, 200-day A$15.98: 150-day is not above the 200-day
- 2. 200-day trending up: pass. 200-day average A$15.98 vs A$15.86 a month ago (+0.8%)
- 3. Well off the low: pass. Close A$19.82 is 80.2% above the 52-week low of A$11.00
- 4. Near the high: pass. 16.6% below the 52-week high
- 5. Relative strength: pass. 6-month relative strength +66.3 points, in the top quartile (cut-off +7.8)
- 6. Above the 50-day: fail. Close A$19.82 vs 50-day average A$20.46 (-3.1%)
- 7. Liquid enough to trade: pass. A$8.1m average daily turnover over 20 sessions
Crowded-Short Breakout
WatchScore 35rank 118 of 1611
- 1. Crowded short: fail. 2.99% of shares on issue reported short, under 5%
- 2. Days to cover: pass. 8.0 days of average volume to cover
- 3. Breakout on heavy volume: fail. No close above the A$23.76 pivot on 1.5x volume in the last 5 sessions; close is -16.6% from the pivot
- 4. Market direction: fail. XJO in a downtrend: below its 200-day average
- 5. Liquid enough to trade: pass. A$8.1m average daily turnover over 20 sessions
- 6. Relative strength: pass. Beat the S&P/ASX 200 by 63.4 points over 3 months
Quality compounders
WatchScore 39rank 13 of 1171
- 1. High return on equity: unknown. Return on equity cannot be measured: it needs net profit, equity at both ends of the year and, outside banks, insurers and other financials, equity of at least 10% of total assets
- 2. Healthy profit margin: pass. Net margin 47.1% (FY ending 2025-06-30)
- 3. Profit that turns into cash: unknown. Free cash flow or net profit is missing for the period
- 4. Little debt: unknown. Net debt cannot be measured: no aligned balance sheet with debt and cash
- 5. Liquid enough to trade: pass. A$8.1m average daily turnover over 20 sessions
- 6. Long-term uptrend: pass. Close A$19.82 vs 200-day average A$15.98 (+24.0%)
- 7. Revenue not shrinking: unknown. No revenue growth figure yet